

Curis to Present at the 60th Annual Meeting of the American Society of Hematology

LEXINGTON, Mass., Nov. 20, 2018 [/PRNewswire/](#) -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, today announced three upcoming poster presentations at the 60th annual meeting of the American Society of Hematology. Curis's poster presentations will be available for viewing on Monday, December 3 (Session III) from 10 a.m. to 8 p.m. PT with presentations from 6 p.m. to 8 p.m. PT in Hall GH at the San Diego Convention Center.

Curis will present three posters at the ASH conference providing key information supporting development of fimepinostat in patients with DLBCL, including patients with MYC-alterations, and CA-4948, Curis's IRAK4 inhibitor, for patients with lymphomas. A pooled analysis of R/R DLBCL patients treated with fimepinostat demonstrates adequate safety and anti-tumor activity supporting the biologic rationale for continued development of fimepinostat in this patient population. Additionally, Curis will present preclinical data and biological rationale that support CA-4948 development in patients with tumors sensitive to the IRAK4 signaling pathway as well as data supporting the potential for IRAK4-based combination regimens to overcome drug tolerance in patients with Non-Hodgkin Lymphoma.

Details of these presentations are as follows:

Curis Presentations at American Society of Hematology 60th Annual Meeting

Viewing
Date/Time: Monday, Dec. 3, 10:00 AM – 8:00 PM PT

Presentation
Date/Time: Monday, Dec. 3, 6:00 PM – 8:00 PM PT

Location: Hall GH, San Diego Convention Center

Abstract
Number: 4168

Presentation
Title: *Preclinical Activity of IRAK4 Kinase Inhibitor CA-4948 Alone or in Combination with Targeted Therapies and Preliminary Phase 1 Clinical Results in Non-Hodgkin Lymphoma*

Abstract
Number: 4184

Presentation
Title: *A Pooled Analysis of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients Treated with the Dual PI3K and HDAC Inhibitor Fimepinostat (CUDC-907), Including Patients with MYC-Altered Disease*

Abstract
Number: 2649

Presentation
Drug Combinations Co-Targeting Myeloid Cell Leukemia-1 (Mcl-1) Protein Can

Title: *Overcome Microenvironmentally-Induced Multi-Drug Tolerance in Non-Hodgkin Lymphomas*

About Curis, Inc.

Curis is a biotechnology company focused on the development and commercialization of innovative therapeutics for the treatment of cancer, including fimepinostat, which is being investigated in clinical studies in patients with DLBCL and solid tumors. Curis is also engaged in a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including, the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas, and in a Phase 2 trial in India conducted by Aurigene. CA-4948 is currently undergoing testing in a Phase 1 trial in patients with non-Hodgkin lymphoma. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis's website at www.curis.com.

SOURCE Curis, Inc.

For further information: Investor Relations, Alex Fudukidis, Russo Partners, (646) 942-5632, alex.fudukidis@russopartnersllc.com; Media Contact, David Schull, Russo Partners, (212) 845-4271, david.schull@russopartnersllc.com

<http://investors.curis.com/2018-11-20-Curis-to-Present-at-the-60th-Annual-Meeting-of-the-American-Society-of-Hematology>